Zuidema Mozow Y, Dellsperger Kevin C
Division of Cardiovascular Medicine, Department of Internal Medicine, Columbia, Mo., USA.
Cardiorenal Med. 2012 May;2(2):125-133. doi: 10.1159/000337476. Epub 2012 Mar 30.
We discuss the current state of knowledge related to the pathogenesis of myocardial stunning as well as the potential mechanisms responsible for the clinical presentation of myocardial stunning in hemodialysis patients. We suggest future research areas for this critical and clinically important condition in this high-risk patient population. In consideration of acute and chronic changes secondary to dialysis, especially in patients with risk for coronary artery disease, the prevalence of myocardial stunning and its role in the natural history of these patients' disease progression is considered. We propose a paradigm: that the majority of the pathophysiologic mechanisms by which hemodialysis may induce myocardial stunning falls into two categories with (1) vascular and/or (2) metabolic contributions. In order to prevent eventual myocardial hibernation, myocardial remodeling, scarring, and loss of contractile function with aberrant electrical conductivity that could lead to sudden death, it is imperative to identify the risk factors associated with myocardial stunning during hemodialysis. Further understanding of these mechanisms may lead to novel clinical interventions and pharmacologic therapeutic agents.
我们讨论了与心肌顿抑发病机制相关的当前知识状态,以及血液透析患者中心肌顿抑临床表现的潜在机制。我们提出了针对这一高危患者群体中这种关键且具有临床重要性病症的未来研究领域。考虑到透析继发的急性和慢性变化,特别是在有冠状动脉疾病风险的患者中,探讨了心肌顿抑的患病率及其在这些患者疾病进展自然史中的作用。我们提出一种模式:血液透析可能诱发心肌顿抑的大多数病理生理机制可分为两类,即(1)血管性和/或(2)代谢性因素。为了预防最终的心肌冬眠、心肌重塑、瘢痕形成以及伴有异常电传导的收缩功能丧失(这可能导致猝死),识别血液透析期间与心肌顿抑相关的危险因素至关重要。对这些机制的进一步了解可能会带来新的临床干预措施和药物治疗剂。